AMGN.NASDAQAmgen INC

Form 4: Amgen Executive Reports Stock Disposition

Sentiment:

Statement of Changes in Beneficial Ownership


Amgen EVP and General Counsel Jonathan P. Graham disposed of 499 shares of common stock to cover tax obligations.

Summary

  • Jonathan P. Graham, EVP & General Counsel of Amgen Inc., reported the disposition of 499 shares of common stock.
  • The transaction occurred on May 7, 2026, at a price of $331.11 per share.
  • The disposition was executed via code 'F', indicating the payment of tax liability by withholding shares incident to the vesting of a security.
  • Following this transaction, the reporting person maintains beneficial ownership of 39,712 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a market-driven divestment.

Positives

  • The transaction is a routine administrative action related to tax withholding upon the vesting of equity awards, rather than a discretionary sale.

Negatives

  • Reduction in the total number of shares held directly by a key executive.

Risks

  • None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

Not applicable; this is a historical disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that routine tax-related share withholding is a standard practice among large-cap pharmaceutical executives and does not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

  • The transaction aligns with standard corporate governance practices for equity incentive plan management in the pharmaceutical sector.
  • Similar to practices at peers like Pfizer or Gilead, where executives frequently utilize share withholding to satisfy tax obligations upon RSU vesting.

Stakeholder Impact

  • Minimal impact on shareholders as the transaction is a standard tax-withholding event.

Key Dates

DateDescription
05/07/2026Date of the reported stock disposition transaction.
05/08/2026Date the Form 4 was signed and filed.

Keywords

Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Biotech

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.